Business
SS Innovations Reports Fourth Quarter and Full Year 2025 Financial Results
Strong growth in SSi Mantra installations, procedures and revenues FORT LAUDERDALE, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- SS Innovations International,
About this update from Ss Innovations International Inc.
[{"type":"text","content":"Strong growth in SSi Mantra installations, procedures and revenues\nFORT LAUDERDALE, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three and twelve months ended December 31, 2025. The Company also filed its Annual Report on Form 10-K for the year ended December 31, 2025, with the Securities and Exchange Commission on March 10, 2026. Fourth Quarter 2025 Overview Revenue increased 79.1% to $14.5 million from $8.1 million in the fourth quarter of 2024.Gross margin of 43.9% compared to 48.9% in the fourth quarter of 2024.Gross profit rose 60.7% to $6.4 million from $4.0 million in the fourth quarter of 2024.Net loss of $2.5 million, or $(0.01) per diluted share, compared to a net loss of $1.9 million, or $(0.01) per diluted share, in the fourth quarter of 2024.SSi Mantra surgical robotic system installations totaled 40, up 81.8% from 22 installations in the fourth quarter of 2024 and up 48.1% from 27 installations in the third quarter of 2025. Full Year 2025 Overview Revenue increased 105.7% to $42.5 million from $20.6 million in 2024.Gross margin expanded to 46.0% from 40.9% in 2024.Gross profit rose 131.2% to $19.5 million from $8.5 million in 2024.Net loss of $12.1 million, or $(0.06) per diluted share, compared to net loss of $19.2 million, or $(0.11) per diluted share, in 2024.SSi Mantra surgical robotic system installations totaled 103, up 119.1% from 47 installations in 2024. As of December 31, 2025 Long-term debt of $0.Cash and cash equivalents totaled $3.2 million, excluding restricted cash.SSi Mantra cumulative installed base totaled 168 across ten countries and cumulative surgeries reached 7,885, including 120 telesurgeries, 390 cardiac procedures and 121 pediatric surgeries. CEO Commentary Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “In the fourth quarter of 2025, we achieved strong growth in SSi Mantra installations, procedures and revenues, capping off a successful year for SS Innovations. Among our accomplishments in 2025, we gained significant share of the surgical robotics market in Indi...